KR102210575B1 - 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물 - Google Patents

암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물 Download PDF

Info

Publication number
KR102210575B1
KR102210575B1 KR1020157010519A KR20157010519A KR102210575B1 KR 102210575 B1 KR102210575 B1 KR 102210575B1 KR 1020157010519 A KR1020157010519 A KR 1020157010519A KR 20157010519 A KR20157010519 A KR 20157010519A KR 102210575 B1 KR102210575 B1 KR 102210575B1
Authority
KR
South Korea
Prior art keywords
acid
limited
regorafenib
examples include
acetylsalicylic acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020157010519A
Other languages
English (en)
Korean (ko)
Other versions
KR20150060869A (ko
Inventor
올라프 베버
카를 지겔보이어
Original Assignee
바이엘 파마 악티엔게젤샤프트
바이엘 에이쥐
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46963566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR102210575(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 바이엘 파마 악티엔게젤샤프트, 바이엘 에이쥐 filed Critical 바이엘 파마 악티엔게젤샤프트
Publication of KR20150060869A publication Critical patent/KR20150060869A/ko
Application granted granted Critical
Publication of KR102210575B1 publication Critical patent/KR102210575B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020157010519A 2012-09-25 2013-09-23 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물 Active KR102210575B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185852.6 2012-09-25
EP12185852 2012-09-25
PCT/EP2013/069735 WO2014048881A1 (en) 2012-09-25 2013-09-23 Combination of regorafenib and acetylsalicylic acid for treating cancer

Publications (2)

Publication Number Publication Date
KR20150060869A KR20150060869A (ko) 2015-06-03
KR102210575B1 true KR102210575B1 (ko) 2021-02-02

Family

ID=46963566

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020157010519A Active KR102210575B1 (ko) 2012-09-25 2013-09-23 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물

Country Status (29)

Country Link
US (1) US10898500B2 (https=)
EP (1) EP2900269B1 (https=)
JP (1) JP6294888B2 (https=)
KR (1) KR102210575B1 (https=)
CN (1) CN104994876A (https=)
AU (1) AU2013322854B2 (https=)
BR (1) BR112015006686B1 (https=)
CA (1) CA2885688C (https=)
CL (1) CL2015000744A1 (https=)
CY (1) CY1120939T1 (https=)
DK (1) DK2900269T3 (https=)
EA (1) EA032023B1 (https=)
ES (1) ES2687985T3 (https=)
HK (1) HK1214169A1 (https=)
HR (1) HRP20181462T1 (https=)
HU (1) HUE039878T2 (https=)
IL (1) IL237690B (https=)
LT (1) LT2900269T (https=)
MX (1) MX357035B (https=)
MY (1) MY183969A (https=)
NZ (1) NZ705860A (https=)
PH (1) PH12015500587A1 (https=)
PL (1) PL2900269T3 (https=)
PT (1) PT2900269T (https=)
RS (1) RS57875B1 (https=)
SG (2) SG11201501963RA (https=)
SI (1) SI2900269T1 (https=)
WO (1) WO2014048881A1 (https=)
ZA (1) ZA201502840B (https=)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104364239B (zh) 2012-06-13 2017-08-25 霍夫曼-拉罗奇有限公司 二氮杂螺环烷烃和氮杂螺环烷烃
MX368615B (es) 2012-09-25 2019-10-09 Hoffmann La Roche Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos.
AR095079A1 (es) 2013-03-12 2015-09-16 Hoffmann La Roche Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo
DK3074400T3 (en) 2013-11-26 2018-01-15 Hoffmann La Roche Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors
EA032357B1 (ru) 2014-03-26 2019-05-31 Ф. Хоффманн-Ля Рош Аг Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa)
CA2937616A1 (en) 2014-03-26 2015-10-01 F. Hoffmann-La Roche Ag Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors
CN104829523B (zh) * 2014-04-30 2017-10-31 药源药物化学（上海）有限公司 瑞戈非尼盐及其晶型、制备方法
MA41898A (fr) 2015-04-10 2018-02-13 Hoffmann La Roche Dérivés de quinazolinone bicyclique
CA2992889A1 (en) 2015-09-04 2017-03-09 F. Hoffmann-La Roche Ag Phenoxymethyl derivatives
CN105267167A (zh) * 2015-09-11 2016-01-27 江苏嘉逸医药有限公司 一种瑞戈非尼口服固体药物组合物的制备方法
WO2017050732A1 (en) 2015-09-24 2017-03-30 F. Hoffmann-La Roche Ag Bicyclic compounds as atx inhibitors
JP6876685B2 (ja) 2015-09-24 2021-05-26 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ａｔｘ阻害剤としての二環式化合物
BR112017026682A2 (pt) 2015-09-24 2018-08-14 Hoffmann La Roche novos compostos bicíclicos como inibidores de dupla ação de atx/ca
AU2016328436B2 (en) 2015-09-24 2020-05-14 F. Hoffmann-La Roche Ag New bicyclic compounds as dual ATX/CA inhibitors
PL3474858T3 (pl) * 2016-06-28 2022-01-17 Asamedic As Dwuskładnikowa kompozycja zawierająca kwas acetylosalicylowy
RU2019132254A (ru) 2017-03-16 2021-04-16 Ф. Хоффманн-Ля Рош Аг Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca
JP7090099B2 (ja) 2017-03-16 2022-06-23 エフ．ホフマン－ラ ロシュ アーゲー Ａｔｘインヒビターとしての新規二環式化合物
CA3244313A1 (en) 2017-06-02 2025-06-13 Bayer Healthcare Llc Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer
EP3501522A1 (en) 2017-12-22 2019-06-26 Asamedic AS Compositions comprising acetylsalicylic acid and a phosphate salt
EP3501523A1 (en) 2017-12-22 2019-06-26 Asamedic AS Two-component compositions comprising acetyl salicylic acid and a carbonate salt
KR20210156389A (ko) 2020-06-17 2021-12-27 재단법인대구경북과학기술원 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2373940A1 (en) * 1999-07-02 2001-01-11 Hisamitsu Pharmaceutical Co., Inc. Medicinal compositions for treating colorectal cancer
US20040121004A1 (en) * 2002-12-20 2004-06-24 Rajneesh Taneja Dosage forms containing a PPI, NSAID, and buffer
EP1663978B1 (en) * 2003-07-23 2007-11-28 Bayer Pharmaceuticals Corporation Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
EP1948144A2 (en) * 2005-11-10 2008-07-30 Bayer HealthCare AG Diaryl urea for treating diabetic neuropathy
AR062927A1 (es) 2006-10-11 2008-12-17 Bayer Healthcare Ag 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
GB201002530D0 (en) * 2010-02-15 2010-03-31 Univ Wolverhampton The Di-aspirin derivatives
AR081060A1 (es) 2010-04-15 2012-06-06 Bayer Schering Pharma Ag Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Journal of Cancer, 129 p245-255,2011.*
Lancet, 378, p2081-87,2011.*

Also Published As

Publication number Publication date
BR112015006686B1 (pt) 2022-04-05
DK2900269T3 (en) 2018-10-01
EP2900269B1 (en) 2018-08-01
PH12015500587A1 (en) 2015-05-11
BR112015006686A2 (pt) 2019-08-27
IL237690A0 (en) 2015-05-31
CY1120939T1 (el) 2019-12-11
JP6294888B2 (ja) 2018-03-14
PT2900269T (pt) 2018-10-22
CA2885688C (en) 2021-03-02
SG11201501963RA (en) 2015-04-29
ES2687985T3 (es) 2018-10-30
SI2900269T1 (sl) 2018-10-30
RS57875B1 (sr) 2018-12-31
CL2015000744A1 (es) 2016-01-08
US10898500B2 (en) 2021-01-26
MY183969A (en) 2021-03-17
EA201500365A1 (ru) 2015-08-31
NZ705860A (en) 2018-07-27
MX357035B (es) 2018-06-25
AU2013322854B2 (en) 2018-07-19
HUE039878T2 (hu) 2019-02-28
AU2013322854A1 (en) 2015-04-02
IL237690B (en) 2019-07-31
CN104994876A (zh) 2015-10-21
EA032023B1 (ru) 2019-03-29
HK1214169A1 (zh) 2016-07-22
PL2900269T3 (pl) 2019-02-28
ZA201502840B (en) 2017-11-29
HRP20181462T1 (hr) 2018-11-02
KR20150060869A (ko) 2015-06-03
WO2014048881A1 (en) 2014-04-03
JP2015529234A (ja) 2015-10-05
CA2885688A1 (en) 2014-04-03
US20150202214A1 (en) 2015-07-23
SG10201702356VA (en) 2017-04-27
EP2900269A1 (en) 2015-08-05
LT2900269T (lt) 2018-11-12
MX2015003728A (es) 2015-09-23

Similar Documents

Publication Publication Date Title
KR102210575B1 (ko) 암 치료를 위한 레고라페닙과 아세틸살리실산의 조합물
AU2023282197B2 (en) Combination of regorafenib and PD-1/PD-L1(2) inhibitors for treating cancer
RU2774838C2 (ru) Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака
HK40109111A (zh) 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
HK40105741A (zh) 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品
HK40015063A (en) Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0701 Decision of registration after re-examination

St.27 status event code: A-3-4-F10-F13-rex-PX0701

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 6